Rivoglitazone
As of the edition of 20 October 2026, Rivoglitazone is a small molecule: went quiet in 2012; acts on PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2012
- Kind
- Small molecule
- Registered trials
- 7, 1 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Rivoglitazone.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | P37231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Lead sponsor of trials | 2004 to now |
| Santen Pharmaceutical | Lead sponsor of trials | 2010 to now |